Navigation Links
TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
Date:7/20/2011

SCOTTSDALE, Ariz. July 20, 2011 A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).

The drug under investigation, GDC-0941, manufactured by Genentech Inc., South San Francisco, Calif., targets the PI3K gene, which is abnormal in about 20-30 percent of patients with advanced breast cancer.

In collaboration with the Karmanos Cancer Institute in Detroit, Mich. and the Dana-Farber Cancer Institute in Boston, Mass., Dr. Von Hoff and his team at Virginia G. Piper Cancer Center Clinical Trials initially tested the drug in 97 patients with various advanced cancers. Patients experienced manageable side effects including diarrhea, nausea, taste alteration, rash, fatigue, itchiness, vomiting and decreased appetite.

The study resulted in significant shrinkage of tumors in two patients - one with advanced cervical cancer and one with advanced breast cancer. Another patient with ampullary cancer of the pancreas is currently on the study with stable disease for more than a year.

Dr. Von Hoff is Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Chief Scientific Officer at Scottsdale Healthcare and US Oncology. Virginia G. Piper Cancer Center Clinical Trials is a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

"We are very excited about personalizing therapy for breast cancer and gynecologic cancer patients with PI3K inhibitors," said Dr. Von Hoff, who made his presentation in June during ASCO's annual meeting in Chicago. "The next step will be to test samples from breast cancer patients for PI3K mutations and treat those patients accordingly."

Breast cancer remains one of the deadliest cancers among women, with approximately 180,000 new cases each year.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen, Tecan and ASU Biodesign Institute develop sample preparation solution for proteomic research
2. TGen, UA student-researcher extends string of coveted scholarships
3. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
4. Virginia Bioinformatics Institute to model immune responses to gut pathogens
5. Virginia Tech professor discovers new TB pathogen
6. VCU first Virginia institution to join national network of academic research centers
7. Dr. Phillip Chang Introduces New Ways to Decrease Scars and Potential Complications For Breast Augmentations in Loudoun and Fairfax Virginia
8. Virginia Hospital Shared Services Corporation Selects Verified Credentials as its Exclusively Endorsed Provider of Background Screening Services
9. West Virginia EHR Collaborative Adds New Member
10. Internet Security Problems Solved - A New Internet Security Group Defeats CyberCrime in West Virginia
11. Virginia First State to Pass Health Care Freedom Act: 38 States Lining Up Against ObamaCare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... DC (PRWEB) , ... April 28, 2017 , ... ... Pregnancy (The National Campaign) announces its support for the Access to Contraception ... Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading ... Word(TM) Online(TM), which enables sleep physicians to create and edit their interpretation reports. ... and provides a familiar interface that does not require additional training to use. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
(Date:4/28/2017)... Cypress, California (PRWEB) , ... April 28, 2017 ... ... LED T8 Direct Replace tubes . These lamps offer an instant energy-saving solution ... no need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: